Lymphotropic nanoparticle-enhanced MRI in prostate cancer: Value and therapeutic potential

Current Urology Reports

Volumn 15, Issue 3, 2014, Pages

  Fortuin, Ansje S ^a   Smeenk, Robert Jan ^a   Meijer, Hanneke J M ^a   Witjes, Alfred J ^a   Barentsz, Jelle O ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combidex; Ferumoxtran 10; Lymph Node Metastases; MRI; MRL; Nanoparticle; Prostate Cancer; Urology; USPIO

Indexed keywords

LYMPHOTROPIC NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DEXTRAN; DIAGNOSTIC AGENT; FERUMOXTRAN-10; MAGNETITE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; HUMAN; IMAGE ENHANCEMENT; LYMPH NODE; LYMPH NODE METASTASIS; MAGNETIC RESONANCE LYMPHOGRAPHY; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; CANCER STAGING; IMAGE GUIDED RADIOTHERAPY; LYMPH NODE DISSECTION; LYMPHOGRAPHY; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; RADIOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY;

CONTRAST MEDIA; DEXTRANS; HUMANS; LYMPH NODE EXCISION; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; LYMPHOGRAPHY; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; SENSITIVITY AND SPECIFICITY;

EID: 84891897040     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0389-7     Document Type: Article

References (55)

1. Hövels A, Heesakkers R, Adang E, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin rad. 2008;63:387-95.
2. Heesakkers R, Jager G, Hövels A, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR Imaging. Radiology. 2009;251:408-14.
3. .•• Joniau S, van den Bergh L, Lerut E, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur urol. 2013;63:450-8. In this article, lymphatic drainage and discrimination patterns of prostate cancer were presented. Standard PLND would have correctly staged the majority of lymph node-positive patients, but 13% of the positive lymph nodes would be missed..
4. Makarov D, Trock B, Humphreys E, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason Score (Partin tables) based on cases from 2000-2005. Urology. 2007;69:1095-101. (Pubitemid 46891611)
5. Roach IIIM,Marquez C, You H. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33-7. (Pubitemid 24012852)
6. Deserno W, Debats O, Rozema T, et al. Comparison of nodal risk formula and MR Lymphography for predicting lymph node involvement in prostate cancer. Int J Rad Oncol Biol Phys. 2011;81:8-15.
7. Nguyen P, Chen M, Hoffman K, et al. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys. 2009;74:104-9.
8. Bellin MF, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. Eur J Rad. 2000;34:257-64. (Pubitemid 30601698)
9. Fortuin A, Deserno W, Meijer H, et al. Value of PET/CT and MR Lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Rad Oncol Biol Phys. 2012;84:712-8.
10. Harisinghani MG, Saini S, Weissleder R, et al. Ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathological correlation. AJR. 1999;172:1347-51. (Pubitemid 29508795)
11. Harisinghani M, Barentsz J, Hahn P, et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer. Acad Radiol. 2002;9:s312-3. (Pubitemid 34857704)
12. Harisinghani M, Barentsz J, Hahn P, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-9. (Pubitemid 36706536)
13. Deserno WMLLG, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004;233:449-56. (Pubitemid 39423804)
14. Tabatabaei S, Harisinghani MG, McDougal WS. Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. J Urol. 2005;174:923-7. (Pubitemid 41140632)
15. Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphtrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology. 2005;66:1066-71. (Pubitemid 41587162)
16. Harisinghani MG, Saksena MA, Hahn PF, et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR. 2006;186:144-8. (Pubitemid 46100376)
17. Guimaraes AR, Tabatabei S, Dahl D, et al. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology. 2008;71:708-12.
18. Heesakkers R, Hovels A, Jager G, et al. MRI with a lymph-node-specific contrast agent as an alternative to CTscan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9:850-6.
19. Thoeny H, Triantafyllou M, Birkhäuser F, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761-9.
20. Triantafyllou M, Studer U, Birkhäuser F, et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer. 2013;49:616-24.
21. .• Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol. 2013; in press. Most recent article on MRL, with the addition of a DWI sequence to the protocol, resulting in reduction of reading time.
22. Wu L, Cao Y, Liao C, Huang J, Gao F. Diagnostic performance of USPIO-enhanced MRI for lymph-nodemetastases in different body regions: a meta-analysis. Eur J Rad. 2011;80:582-9.
23. Fortuin AS, Meijer H, Thomson LC, Witjes JA, Barentsz JO. Ferumoxtran-10 (USPIO)-enhanced DWI-MRI for detection of metastases in normal-sized lymph nodes in patients with bladder and prostate cancer: do we enter the era after ePLND? Editorial. Eur Urol. 2013; in press.
24. Fortuin A, Barentsz J. Comments on Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer. 2013;49:1789-90.
25. Evangelista L, Guttilla A, Zattoni F, et al. Utility of choline positron tomography/computed tomography for lymph node involvement identification in intermediate-to-high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol. 2013;63:1040-8.
26. Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [11C] choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2013; Epub ahead of print.
27. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68GA]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-95.
28. Eder M, Schäfer M, Bauder-Wüst U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-97.
29. Afshar-Oromieh A, Haberkorn U, Hadaschik B. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging. 2013; Epub ahead of print.
30. Roethke M, Kuru TH, Afshar-Oromieh A, et al. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. 2013; Epub ahead of print.
31. Banerjee S, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-41.
32. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [68GA]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012; 39:1085-1086.
33. .•• Meijer H, Fortuin A, van Lin E, et al. Geographical distribution of lymph node metastases on MR lymphography in prostate cancer patients. Radiother Oncol. 2013;106:59-63. MRL-based study presenting the distribution of lymph node metastases in primary prostate cancer patients. 53% of patients had a positive lymph node outside the standard radiation field.
34. .•• Meijer H, Van Lin E, Debats O, et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy 2012. Int J Rad Oncol Biol Phys. 2012;82:1405-10. MRL-based study presenting the distribution of lymph node metastases in prostate cancer patients with recurrence. 79% of patients had at least one positive lymph node outside the standard radiation field..
35. Joslyn S, Konety B. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006;68:121-5. (Pubitemid 44037727)
36. Burkhard F, Studer U. The role of lymphadenectomy in high-risk prostate cancer. World J Urol. 2008;26:231-6.
37. Thurairaja R, Studer U, Burkhard F. Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist. 2009;14:40-51.
38. Allaf M, Palapattu G, Trock B, Carter H, Walsh P. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172:1840.
39. Cheng L, Zincke H, Blute M, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. American cancer society. 2001;91:66-73.
40. Fleischmann A, Schobinger S, Schumacher M, Thalmann G, Studer U. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate. 2009;69:352-62.
41. Meijer H, Debats O, van Lin E, et al. A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography:whomight be cured? Radiat Oncol. 2013; 8:Epub ahead of print.
42. RTOG 94-13 A phase III trial comparing whole pelvic irradiation followed by a conedown boost to boost irradiation only and comparing neoadjuvant to adjuvant total androgen suppression (TAS).
43. Adkinson J, McHaffie D, Bentzen S, et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:184-90.
44. Ganswindt U, Paulsen F, Corvin S, et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition.BMC Cancer. 2005;5:91.
45. Meijer H, Debats O, Kunze-Busch M, et al. Magnetic resonance lymphography-guided selective high dose lymph node irradiation in prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:175-83.
46. Meijer H, Debats O, van Lin E, et al. Individualized image-based lymph node irradiation for prostate cancer. Nat Rev Urol. 2013;10:376-85.
47. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011; 6:44.
48. Weidner A, van Lin E, Dinter D, et al. Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse. Strahlenther Oncol. 2011;187:206-2012.
49. Souvatzoglou M. Krause, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99:193-200.
50. Jereczek-Fossa B, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14-7.
51. Jereczek-Fossa B, Beltramo G, Fariselli L, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889-97.
52. Casamassima F,Masi L, Menichelli C, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori. 2011;97:49-55.
53. Berkovic P, De Meerleer G, Delrue L, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11:27-32.
54. Kishi K, Sonomura T, Shirai S, et al. Reirradiation of paraaortic lymph nodemetastasis by brachytherapy with hyaluronate injection via paravertebral approach: with DVH comparison to IMRT. Brachytherapy. 2013;12:8-13.
55. Hövels A, Heesakkers R, Adang E, et al. Cost-effectiveness of MR Lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology. 2009;252:729-36.